DENVER--(BUSINESS WIRE)--Accelr8 Technology Corporation (NYSE Amex: AXK) today announced that it has received acceptance to present results for a study on 2-hour, culture-free, quantitative pathogen identification. The study was co-authored with principal investigators at the Denver Health Medical Center and the Barnes-Jewish Hospital in St. Louis. The presentation will take place at the 110th General Meeting of the American Society for Microbiology (ASM, www.asm.org) to be held from May 23-27 in San Diego. Tests performed directly from specimens accurately identified three target pathogens that are the most resistance–prone bacteria responsible for hospital-acquired infections (HAI).
